>
Fa   |   Ar   |   En
   Etanercept in erythema nodosum leprosum  
   
نویسنده santos j.r.s. ,vendramini d.l. ,nery j.a.c. ,avelleira j.c.r.
منبع journal brazilian annals of dermatology - 2017 - دوره : 92 - شماره : 4 - صفحه:575 -577
چکیده    One of the biggest challenges in treating leprosy is the control of reaction events. patients with lepromatous leprosy may present reaction type ii,or erythema nodosum leprosum,during treatment,and this reaction can remain in a recurrent form after being released from the hospital,requiring the use of thalidomide and/or prednisone for long periods of time,in turn increasing the risk of side effects. two reports of the use of antitnf to treat erythema nodosum leprosum were found in the literature. a good response was found after an assay with infliximab and etanercept. this study reports on a patient with lepromatous leprosy and recurrent reaction,controlled by using etanercept and a 10-month follow-up,with the interruption of thalidomide and the maintenance of prednisone at 10 mg/day. © 2017 by anais brasileiros de dermatologia.
کلیدواژه Erythema nodosum; Leprosy; Tumor necrosis factor-alpha
آدرس professor rubem david azulay dermatology,santa casa de misericórdia do rio de janeiro (dprda-scmrj),rio de janeiro,rj, Brazil, professor rubem david azulay dermatology,santa casa de misericórdia do rio de janeiro (dprda-scmrj),rio de janeiro,rj, Brazil, professor rubem david azulay dermatology,santa casa de misericórdia do rio de janeiro (dprda-scmrj),rio de janeiro,rj,brazil,leprosy laboratory,fundação oswaldo cruz,fiocruz,rio de janeiro,rj, Brazil, professor rubem david azulay dermatology,santa casa de misericórdia do rio de janeiro (dprda-scmrj),rio de janeiro,rj,brazil,dermatology service,hospital federal da lagoa,rio de janeiro,rj, Brazil
 
     
   
Authors
  
 
 

Copyright 2023
Islamic World Science Citation Center
All Rights Reserved